Other therapeutic complications.
And I mentioned when you have marrow
ablation, you're going to have,
going to be at a profound
risk of developing infections.
Here we're showing the heart on a patient
who had acute Myelogenous Leukemia, AML
got successful chemotherapy that killed off the
tumor, but at the same time caused neutropenia.
In the left atrium here, you can see a rather
large fungating mass extending down on to the valve
And when we looked at that
histologically, it ended up being fungus.
It is a huge fungus ball.
You can actually see the filamentous fibers
on the left hand side on a standard H and E
with the inflammatory response around them.
They are better highlighted with the methenamine
silver stain that you see on the right.
And this patient died not because of
their AML but because of the chemotherapy
that we gave them to treat the AML
that led to a systemic fungal infection
that the patient couldn't fight off
because they didn't have neutrophils,
or a good, robust T-cell response.
So with that kind of morbid thing in
mind, most of the time, a lot of the time,
we're successful in treating cancers,
we're getting better and better
but because of the unwanted untoward side
effects that can occur with any of our therapies,
right now, we can't do therapy with
surgical precision that just gets the cancer
and doesn't have consequences elsewhere.
So just keep that in mind, and hopefully, one
of you, many of you will help us do a better job
of arriving really targeted
therapy for cancer patients.